Here are four takeaways:
1. Ocaliva (obeticholic acid) is intended for the treatment of patients with primary biliary cirrhosis, recently renamed primary biliary cholangitis.
2. The drug is specifically intended for the treatment of PBC in patients with an inadequate response to, or who are unable to tolerate, ursodeoxycholic acid.
3. If approved, Ocaliva would be the first new treatment for PBC in nearly 20 years.
4. The FDA is not bound by the advisory committee’s guidance, but takes its advice into consideration.
More articles on GI/endoscopy:
ACA, Medicare, ACOs & more: 5 things to know on gastroenterologist pay
5 most read GI/endoscopy stories: April 11 – April 15
NanoAntibiotics acquires company developing medicines for liver cirrhosis complications: 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.